A gene expression database for the molecular pharmacology of cancer (original) (raw)

• Boyd, M.R. & Paull, K.D. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev. Res. 34, 91– 109 (1995).
  Article CAS Google Scholar
• Alley, M.C. et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48, 589–601 (1988).
  CAS PubMed Google Scholar
• Monks, A. et al. Feasibility of a high flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J. Natl Cancer Inst. 83, 757–766 (1991).
  Article CAS Google Scholar
• Grever, M.R., Schepartz, S.A. & Chabner, B.A. The National Cancer Institute: cancer drug discovery and development program. Semin. Oncol. 19, 622–638 (1992).
  CAS PubMed Google Scholar
• Stinson, S.F. et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res. 12, 1035–1053 (1992).
  CAS PubMed Google Scholar
• Boyd, M.R. in Anticancer Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval (ed. Teicher, B.A.) 23–42 (Humana Press, Totowa, 1997).
  Book Google Scholar
• Ross, D.T. et al. Systematic variation in gene expression patterns in human cancer cell lines. Nature Genet. 24, 227– 235 (2000).
  Article CAS Google Scholar
• Weinstein, J.N. et al. An information-intensive approach to the molecular pharmacology of cancer. Science 275, 343– 349 (1997).
  Article CAS Google Scholar
• Weinstein, J.N. et al. Neural computing in cancer drug development: predicting mechanism of action. Science 258, 447– 451 (1992).
  Article CAS Google Scholar
• van Osdol, W.W., Myers, T.G., Paull, K.D., Kohn, K.W. & Weinstein, J.N. Use of the Kohonen self-organizing map to study the mechanisms of action of chemotherapeutic agents. J. Natl Cancer Inst. 86, 1853–1859 ( 1994).
  Article CAS Google Scholar
• Paull, K.D., Hamel, E. & Malspeis, L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute. in Cancer Chemotherapeutic Agents (ed. Foye, W.E.) 1574– 1581 (American Chemical Soc. Books, Washington, DC, 1993).
  Google Scholar
• Paull, K.D. et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J. Natl Cancer Inst. 81, 1088 –1092 (1989).
  Article CAS Google Scholar
• Shi, L.M., Fan, Y., Myers, T.G., Paull, K.D. & Weinstein, J.N. Mining the NCI anticancer drug discovery databases: genetic function approximation for the quantitative structure-activity relationship study of anticancer ellipticine analogs. J. Chem. Inf. Comput. Sci. 38, 189–199 ( 1998).
  Article CAS Google Scholar
• Shi, L.M. et al. Mining the National Cancer Institute's anticancer drug screen database: cluster analysis of ellipticine analogs with p53-inverse and central nervous system-selective patterns of activity. Mol. Pharmacol. 53, 241–251 (1998).
  Article CAS Google Scholar
• Alvarez, M. et al. Generation of a drug resistance profile by quantitation of MDR-1/P-glycoprotein expression in the cell lines of the NCI anticancer drug screen. J. Clin. Invest. 95, 2205– 2214 (1995).
  Article CAS Google Scholar
• Izquierdo, M.A. et al. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines. Int. J. Cancer 65, 230–237 (1996).
  Article CAS Google Scholar
• O'Connor, P.M. et al. Characterization of the p53-tumor suppressor pathway in cells of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res. 57, 4285–4300 ( 1997).
  CAS PubMed Google Scholar
• Freije, J.M. et al. Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines . Nature Med. 3, 395–401 (1997).
  Article CAS Google Scholar
• Koo, H.-M. et al. Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. J. Natl Cancer Inst. 56, 5211 –5216 (1996).
  CAS Google Scholar
• Wosikowski, K. et al. Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns. J. Natl Cancer Inst. 89, 1505–1513 (1997).
  Article CAS Google Scholar
• Bates, S.E. et al. Reversal of multidrug resistance. Prog. Clin. Biol. Res. 389, 33–37 ( 1994).
  CAS PubMed Google Scholar
• Bates, S.E. et al. Molecular targets in the National Cancer Institute drug screen . J. Cancer Res. Clin. Oncol. 121, 495– 500 (1995).
  Article CAS Google Scholar
• Lee, J.-S. et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol. Pharmacol. 46, 627–638 (1994).
  CAS PubMed Google Scholar
• Wu, L. et al. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening. Cancer Res . 52, 3029–3034 ( 1992).
  CAS PubMed Google Scholar
• Kitada, S. et al. Expression and location of pro-apoptotic Bcl-2 family protein BAD in normal human tissues and tumor cell lines. Am. J. Pathol . 152, 51–61 ( 1998).
  CAS PubMed PubMed Central Google Scholar
• Monks, A., Scudiero, D.A., Johnson, G.S., Paull, K.D. & Sausville, E.A. The NCI anti-cancer drug screen: a smart screen to identify effectors of novel targets. Anticancer Drug Des. 12, 533–541 ( 1997).
  CAS PubMed Google Scholar
• Weinstein, J.N. Fishing expeditions. Science 282, 627 (1998).
  Article Google Scholar
• Myers, T.G. et al. A protein expression database for the molecular pharmacology of cancer. Electrophoresis 18, 647– 653 (1997).
  Article CAS Google Scholar
• Schena, M., Shalon, D., Davis, R.W. & Brown, P.O. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270, 467–470 ( 1995).
  Article CAS Google Scholar
• Schena, M. et al. Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes. Proc. Natl Acad. Sci. USA 93, 10614–10619 (1996).
  Article CAS Google Scholar
• DeRisi, J. et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nature Genet. 14, 457– 460 (1996).
  Article CAS Google Scholar
• Scudiero, D.A., Monks, A. & Sausville, E.A. Cell line designation change: multidrug-resistant cell line in the NCI anticancer screen. J. Natl Cancer Inst. 90, 862 (1998).
• Capranico, G. et al. Mapping drug interactions at the covalent topoisomerase II-DNA complex by bisantrene/amsacrine congeners. J. Biol. Chem. 273, 12732–12739 (1998).
  Article CAS Google Scholar
• Chen, A.Y. & Liu, L.F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol. 94, 194–218 (1994).
  Google Scholar
• Pommier, Y., Tanizawa, A. & Kohn, K.W. Mechanism of topoisomerase I inhibition by anticancer drugs. Adv. Pharmacol. 29B, 73– 92 (1993).
  Google Scholar
• Shao, R.-G. et al. Replication-mediated DNA damage by camptothecin induces phosphorylation of RPA by DNA-dependent protein kinase and dissociates RPA:DNA-PK complexes . EMBO J. (in press).
• Pommier, Y. DNA topoisomease II inhibitors. in Cancer Therapeutics: Experimental and Clinical Agents (ed. Teicher, B.A.) 153–174 (Humana Press, Totowa, 1997).
  Book Google Scholar
• Weinstein, J.N. et al. Predictive statistics and artificial intelligence in the U.S. National Cancer Institute's drug discovery program for cancer and AIDS. Stem Cells 12, 13–22 ( 1994).
  Article CAS Google Scholar
• Eisen, M.B., Spellman, P.T., Brown, P.O. & Botstein, D. Cluster analysis and display of genome-wide expression patterns. Proc. Natl Acad. Sci. USA 95, 14863– 14868 (1998).
  Article CAS Google Scholar
• Fischel, J.L. et al. Dihydropyrimidine dehydrogenase: a tumoral target for fluorouracil modulation. Clin. Cancer Res. 1, 991– 996 (1995).
  CAS PubMed Google Scholar
• McLeod, H.L. et al. Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. Br. J. Cancer 77, 461 –465 (1998).
  Article CAS Google Scholar
• Cooney, D.A. & Handschumacher, R.E. L-asparaginase and L-asparagine metabolism. Annu. Rev. Pharmacol. 10, 421 –440 (1970).
  Article CAS Google Scholar
• Capizzi, R.L., Bertino, J.R. & Handschumacher, R.E. L-Asparaginase. Annu. Rev. Med. 21, 433–444 (1970).
  Article CAS Google Scholar
• Efron, B. & Gong, G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am. Statistician 37, 36–48 (1983).
  Google Scholar
• Wada, H. et al. Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann. NY Acad. Sci. 613, 95–108 (1990).
  Article CAS Google Scholar
• Tanabe, L. et al. MedMiner: an internet tool for mining the biomedical literature, with application to gene expression profiling. Biotechniques 27, 1210–1217 (1999).
  Article CAS Google Scholar
• Brown, P.O. & Botstein, D. Exploring the new world of the genome with DNA microarrays. Nature Genet. 21 (suppl.), 33–37 (1999 ).
  Article CAS Google Scholar
• Shalon, D., Smith, S.J. & Brown, P.O. A DNA microarray system for analyzing complex DNA samples using two-color fluorescent probe hybridization. Genome Res. 6, 639–645 ( 1996).
  Article CAS Google Scholar